The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Metabolic Bone Disease in Chronic Kidney Disease
Abstract
Metabolic bone disease is a common complication of chronic kidney disease (CKD) and is part of a broad spectrum of disorders of mineral metabolism that occur in this clinical setting and result in both skeletal and extraskeletal consequences. Detailed research in that past 4 decades has uncovered many of the mechanisms that are involved in the initiation and maintenance of the disturbances of bone and mineral metabolism and has been translated successfully from "bench to bedside" so that efficient therapeutic strategies now are available to control the complications of disturbed mineral metabolism. Recent emphasis is on the need to begin therapy early in the course of CKD. Central to the assessment of disturbances in bone and mineral metabolism is the ability to make an accurate assessment of the bone disease by noninvasive means. This remains somewhat problematic, and although measurements of parathyroid hormone are essential, recently recognized difficulties with these assays make it difficult to provide precise clinical practice guidelines for the various stages of CKD at the present time. Further research and progress in this area continue to evaluate the appropriate interventions to integrate therapies for both the skeletal and extraskeletal consequences with a view toward improving patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Norman, A. W. (1979) · Cited by 3,769
Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., Ott, S., Sprague, S., Lameire, N., & Eknoyan, G. (2006) · Kidney International · doi:10.1038/sj.ki.5000414 · Cited by 1,993
Self-citationSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462
Bone metabolism and disease in chronic kidney disease
Eknoyan, G., Levin, A., & Levin, N. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00905-3 · Cited by 1,286
An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3
Nykjaer, A., Dragun, D., Walther, D., Vorum, H., Jacobsen, C., Herz, J., Melsen, F., Christensen, E. I., & Willnow, T. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80655-8 · Cited by 1,027
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022536 · Cited by 927
Gutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 921
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus
Tanaka, Y., & Deluca, H. F. (1973) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(73)90010-6 · Cited by 780
Fukuda, N., Tanaka, H., Tominaga, Y., Fukagawa, M., Kurokawa, K., & Seino, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116720 · Cited by 596
Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, M., Dusso, A., MacDonald, P. N., & Brown, A. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118701 · Cited by 511
Kifor, O. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.4.1598 · Cited by 500
Silver, J., Russell, J., & Sherwood, L. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4270 · Cited by 495
Gogusev, J., Duchambon, P., Hory, B., Giovannini, M., Goureau, Y., Sarfati, E., & Drüeke, T. B. (1997) · Kidney International · doi:10.1038/ki.1997.41 · Cited by 493
On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog
Slatopolsky, E., Caglar, S., Pennell, J. P., Taggart, D. D., Canterbury, J. M., Reiss, E., & Bricker, N. S. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106517 · Cited by 481
Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease
González, E. A., Sachdeva, A., Oliver, D. A., & Martin, K. J. (2004) · American Journal of Nephrology · doi:10.1159/000081023 · Cited by 442
Self-citationPerwad, F., Azam, N., Zhang, M. Y. H., Yamashita, T., Tenenhouse, H. S., & Portale, A. A. (2005) · Endocrinology · doi:10.1210/en.2005-0777 · Cited by 425
A novel mechanism for skeletal resistance in uremia
Slatopolsky, E., Finch, J., Clay, P., Martin, D., Sicard, G., Singer, G., Gao, P., Cantor, T., & Dusso, A. (2000) · Kidney International · doi:10.1016/s0085-2538(15)47156-x · Cited by 421
Naveh-Many, T., Rahamimov, R., Livni, N., & Silver, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118224 · Cited by 409
Panda, D. K., Miao, D., Bolivar, I., Li, J., Huo, R., Hendy, G. N., & Goltzman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310271200 · Cited by 393
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
Sprague, S. M., Llach, F., Amdahl, M., Taccetta, C., & Batlle, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00878.x · Cited by 392
Portale, A. A., Booth, B. E., Halloran, B. P., & Morris, R. C. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111365 · Cited by 353
Martin, K. J., González, E. A., Gellens, M., Hamm, L. L., Abboud, H., & Lindberg, J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v981427 · Cited by 346
Self-citationDirect effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro
Almaden, Y., Canalejo, A., Hernandez, A., Ballesteros, E., Garcia-Navarro, S., Torres, A., Rodriguez, M., & Rodriguez, M. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110714 · Cited by 329
Torres, A., Lorenzo, V., Hernández, D., Rodríguez, J. C., Teresa Concepción, M., Rodríguez, A. P., Hernández, A., de Bonis, E., Darias, E., González-Posada, J. M., et al. (1995) · Kidney International · doi:10.1038/ki.1995.201 · Cited by 326
On the Pathogenesis of the Uremic State: An Exposition of the “Trade-off Hypothesis”
Bricker, N. S. (1972) · New England Journal of Medicine · doi:10.1056/nejm197205182862009 · Cited by 319
Chertow, G. M., Burke, S. K., Dillon, M. A., & Slatopolsky, E. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.12.2907 · Cited by 296
Inter-method variability in PTH measurement: Implication for the care of CKD patients
Souberbielle, J.-C., Boutten, A., Carlier, M.-C., Chevenne, D., Coumaros, G., Lawson-Body, E., Massart, C., Monge, M., Myara, J., Parent, X., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001606 · Cited by 290
Brossard, J. H. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.3923 · Cited by 281
The association of nephrolithiasis with cystic fibrosis
Gibney, E. M., & Goldfarb, D. S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00403-7 · Cited by 272
Wada, M., Furuya, Y., Sakiyama, J., Kobayashi, N., Miyata, S., Ishii, H., & Nagano, N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119851 · Cited by 255
SUPPRESSION BY 1,25(OH)2D3OF TRANSCRIPTION OF THE PRE–PR0PARATHYR0ID HORMONE GENE
RUSSELL, J., LETTIERI, D., & SHERWOOD, L. M. (1986) · Endocrinology · doi:10.1210/endo-119-6-2864 · Cited by 244
Martinez, I., Saracho, R., Montenegro, J., & Llach, F. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90330-9 · Cited by 234
Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD
Coyne, D., Acharya, M., Qiu, P., Abboud, H., Batlle, D., Rosansky, S., Fadem, S., Levine, B., Williams, L., Andress, D. L., et al. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.007 · Cited by 227
Slatopolsky, E., & Bricker, N. S. (1973) · Kidney International · doi:10.1038/ki.1973.92 · Cited by 220
Parathyroid hormone gene expression in hypophosphatemic rats.
Kilav, R., Silver, J., & Naveh-Many, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118038 · Cited by 199
Almaden, Y., Hernandez, A., Torregrosa, V, Canalejo, A., Sabate, L., Fernandez Cruz, L., Campistol, J. M., Torres, A., & Rodriguez, M. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9101845 · Cited by 191
Nguyen-Yamamoto, L. (2001) · Endocrinology · doi:10.1210/en.142.4.1386 · Cited by 178
Coburn, J. W., Maung, H. M., Elangovan, L., Germain, M. J., Lindberg, J. S., Sprague, S. M., Williams, M. E., & Bishop, C. W. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.01.012 · Cited by 174
Skeletal resistance to the calcemic action of parathyroid hormone in uremia: Role of 1,25(OH)2D3
Massry, S. G., Stein, R., Garty, J., Arieff, A. I., Coburn, J. W., Norman, A. W., & Friedler, R. M. (1976) · Kidney International · doi:10.1038/ki.1976.60 · Cited by 172
Sela-Brown, A., Silver, J., Brewer, G., & Naveh‐Many, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7424 · Cited by 152
Vascular calcification and renal osteodystrophy relationship in chronic kidney disease
Moe, S. M. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01665.x · Cited by 149
Pathogenesis of Secondary Hyperparathyroidism
Slatopolsky, E., & Delmez, J. A. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80977-2 · Cited by 145
Altered divalent ion metabolism in early renal failure: Role of 1,25(OH)2D
Wilson, L., Felsenfeld, A. J., Drezner, M. K., & Llach, F. (1985) · Kidney International · doi:10.1038/ki.1985.48 · Cited by 124
Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia
Merke, J., Hügel, U., Zlotkowski, A., Szabó, A., Bommer, J., Mall, G., & Ritz, E. (1987) · Kidney International · doi:10.1038/ki.1987.216 · Cited by 116
1 -Hydroxyvitamin D2 is Less Toxic than 1 -Hydroxyvitamin D3 in the Rat
Sjoden, G., Smith, C. M., Lindgren, U., & Deluca, H. F. (1985) · Experimental Biology and Medicine · doi:10.3181/00379727-178-42028 · Cited by 116
Mizobuchi, M., Hatamura, I., Ogata, E., Saji, F., Uda, S., Shiizaki, K., Sakaguchi, T., Negi, S., Kinugasa, E., Koshikawa, S., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000141016.20133.33 · Cited by 114
Lund, R. J., Davies, M. R. P., Brown, A. J., & Hruska, K. A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000109671.99498.08 · Cited by 111
Tatsumi, S., Segawa, H., Morita, K., Haga, H., Kouda, T., Yamamoto, H., Inoue, Y., Nii, T., Katai, K., Taketani, Y., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5925 · Cited by 109
Dusso, A., Pavlopoulos, T., Naumovich, L., Lü, Y., Finch, J. L., Brown, A. J., Morrissey, J. J., & Slatopolsky, E. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059003855.x · Cited by 107
The response to the infusion of parathyroid extract in hypocalcaemic states.
Evanson, J. M. (1966) · PubMed · Cited by 103
Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7
González, E. A., Lund, R. J., Martin, K. J., McCartney, J. E., Tondravi, M. M., Sampath, T. K., & Hruska, K. A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00258.x · Cited by 95
Self-citationLangub, M. C., Monier‐Faugere, M., Wang, G., Williams, J. P., Koszewski, N. J., & Malluche, H. H. (2003) · Endocrinology · doi:10.1210/en.2002-221026 · Cited by 93
Yi, H., Fukagawa, M., Yamato, H., et al. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000188591 · Cited by 81
The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?
Malluche, H. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1002 · Cited by 81
Somerville, P. J., & Kaye, M. (1979) · Kidney International · doi:10.1038/ki.1979.165 · Cited by 78
Resistance to parathyroid hormone in renal failure: Role of vitamin D metabolites
Somerville, P. J., & Kaye, M. (1978) · Kidney International · doi:10.1038/ki.1978.116 · Cited by 67
Long-Term Effects of High Phosphate Intake on Parathyroid Hormone Levels and Bone Metabolism
Jowsey, J., Reiss, E., & Canterbury, J. M. (1974) · Acta Orthopaedica Scandinavica · doi:10.3109/17453677408989691 · Cited by 63
With or without the kidney: the role of FGF23 in CKD
Fukagawa, M., & Kazama, J. J. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh827 · Cited by 63
Mawer, E. B., Jones, G., Davies, M., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4841 · Cited by 62
Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone
Galcerán, T., Martin, K. J., Morrissey, J. J., & Slatopolsky, E. (1987) · Kidney International · doi:10.1038/ki.1987.279 · Cited by 61
Self-citationLewin, E., Garfia, B., Luque, F., Rodríguez, M., & Ølgaard, K. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000024439.38838.03 · Cited by 59
Pathogenic mechanisms for parathyroid hyperplasia
Dusso, A., Sato, T., Arcidiacono, M. V., Álvarez-Hernández, D., Yang, J., González-Suárez, I., Tominaga, Y., & Slatopolsky, E. (2006) · Kidney International · doi:10.1038/sj.ki.5001595 · Cited by 51
Lopez, I., & Buchman, A. L. (2000) · Current Gastroenterology Reports · doi:10.1007/s11894-000-0025-9 · Cited by 44
Yalçındağ, C., Silver, J., & Naveh‐Many, T. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10122562 · Cited by 44
Aluminum and renal osteodystrophy A diminishing clinical problem
González, E. A., & Martin, K. J. (1992) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(92)90004-k · Cited by 18
Self-citation
Cited by
Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease
Podkowińska, A., & Formanowicz, D. (2020) · Antioxidants · doi:10.3390/antiox9080752 · Cited by 356
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
“Phosphate retention begins early in CKD and plays a central role in the development of secondary hyperparathyroidism (SPTH) by inducing hypocalcemia, decreasing calcitriol synthesis, and increasing PTH gene expression [32,33].”
BackgroundThe effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease
Aleksova, J., Ebeling, P., & Elder, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01083-8 · Cited by 20
Metadata
- Authors
- Martin, K. J., & González, E. A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-03
- Volume
- 18
- Issue
- 3
- Pages
- 875-885
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2127561755
- Cited by
- 288
- References
- 66
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.